WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 14, Issue 1, 1041-1056. Review Article ISSN 2277–7105

THE GUT MICROBIOME'S ROLE IN OBESITY-DRIVEN IMMUNE DYSREGULATION AND DIABETES PROGRESSION: MECHANISMS, IMPACTS, AND THERAPEUTIC INSIGHTS

Afsal NA[1], Epparlla Sumanth Babu[2], Md. Ayesha Sultana[3], A. Uma Maheswari[4], Chittepu Charankumar Reddy[5], N. L. Swathi*[6]

[1]Pharm D, Department of Pharmacy Practice, Jawaharlal Nehru Technological University, Anatapuramu, Ananatpur, India.
[2]Department of Pharmacy Practice, Jawaharlal Nehru Technological University, Anatapuramu, Ananatpur, India.
[3]PharmD, Nirmala College of Pharmacy, Atmakur, Mangalagiri, Guntur District, Andhra Pradesh-52250.
[4]Pharm D, Nirmala College of Pharmacy, Atmakur, Mangalagiri, Guntur District, Andhra Pradesh-52250.
[5]Department of Pharmacy Practice, Jawaharlal Nehru Technological University, Anatapuramu, Ananatpur, India.
[6]Department of Pharmacy Practice, Jawaharlal Nehru Technological University, Anatapuramu, Ananatpur, India.

Article Received on
16 Nov. 2024,
Revised on 06 Dec. 2024,
Accepted on 27 Dec. 2024
DOI: 10.20959/wjpr20251-35147

***Corresponding Author**
N. L. Swathi
Department of Pharmacy Practice, Jawaharlal Nehru Technological University, Anatapuramu, Ananatpur, India.

ABSTRACT

The global rise in obesity and diabetes has spotlighted the gut microbiome as a potential link between these conditions. Emerging evidence suggests that gut microbiota-mediated immune responses play a pivotal role in driving chronic inflammation and metabolic dysfunction, which are central to the progression of obesity and diabetes. This review aims to explore the mechanisms by which gut microbiota influences immune responses in obesity and diabetes progression, discuss the current evidence connecting gut dysbiosis with metabolic inflammation, and evaluate therapeutic interventions targeting the gut microbiome. We conducted a narrative review of recent studies on gut microbiome composition in obesity, its role in modulating immune responses, and its downstream effects on insulin resistance and glucose metabolism. Both preclinical and clinical findings were assessed. This article is expected to provide a comprehensive understanding of the gut microbiome's role in obesity

and diabetes, highlighting its contribution to immune-mediated chronic inflammation and metabolic dysfunction. It will also outline promising therapeutic strategies and identify gaps for future research, paving the way for microbiome-targeted interventions in managing metabolic diseases.

1. INTRODUCTION

Obesity, Diabetes, and the Gut Microbiome

The global burden of obesity and diabetes is rising at an alarming rate, significantly contributing to morbidity and mortality across populations. Obesity is a key risk factor for the development of type 2 diabetes mellitus (T2DM), and together these conditions are major public health concerns. Effective approaches must integrate lifestyle changes, pharmacotherapy, and public health interventions to mitigate the escalating incidence of obesity-related diabetes.

The escalating global burden of obesity and diabetes presents significant health challenges that vary geographically and demographically. Recent systematic reviews and meta-analyses underscore the alarming prevalence of obesity as a principal contributor to the development of type 2 diabetes mellitus (T2DM). For instance, two meta-analyses have provided compelling data indicating that the prevalence of obesity has reached epidemic levels, impacting over 1.9 billion adults globally, with associated diabetes prevalence estimated at approximately 415 million individuals, primarily characterized as T2DM, which accounts for over 90% of diagnosed cases of diabetes worldwide.[1,2]

Obesity, defined by a body mass index (BMI) ≥30, leads to a cascade of metabolic dysfunctions, primarily through insulin resistance and inflammation, factors intricately linked to the pathogenesis of T2DM.[1,2] Klein et al.[3] elucidate the complex cellular mechanisms wherein excessive adipose tissue disrupts metabolic homeostasis—resulting in impaired insulin signaling and beta-cell dysfunction. The connection is so profound that obesity is now recognized as a critical factor exacerbating T2DM progression, emphasizing the need for targeted interventions focusing on weight management.

Geographic variations pertain to obesity and diabetes prevalence; for instance, recent data reveals that regions with higher socio-economic statuses exhibit differing incidences of diabetes-related complications, heavily influenced by lifestyle factors rooted in dietary habits and physical activity levels.[4,5] In the United States, the increase in obesity-related diseases

prompts reconsideration of public health strategies, where lifestyle interventions historically have garnered mixed results regarding long-term efficacy.[5,6] The difficulty in maintaining weight loss through lifestyle modifications alone necessitates the exploration of pharmacological solutions. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as an effective pharmacotherapy for reducing weight in obese patients and has also shown promise in improving glycemic control among patients with T2DM, demonstrating a significant 20% reduction in major cardiovascular events when used in conjunction with lifestyle modification.[7]

As the evidence accumulates, there exists a pressing need to reframe obesity not merely as a consequence of individual lifestyle choices but as a public health priority mandating multi-faceted interventions. Barriers such as socio-economic disparities and healthcare access require targeted policies focused on promoting healthier environments conducive to lifestyle transformations. Additionally, public education campaigns emphasizing nutrition, physical activity, and the significance of timely diabetes screening present pivotal elements in addressing the dual burden of obesity and diabetes.[8,9]

The systemic nature of obesity-comorbidities necessitates coordinated efforts involving nutrition, behavioral health, and medical leadership. The intersection of diabetes and obesity illustrates that addressing one entails an urgent response to the other. Multifactorial strategies, including community-level interventions that modify the socio-ecological framework influencing obesity, will be critical in reversing the trends contributing to the rising burden of metabolic diseases globally.[10]

Obesity and Type 2 Diabetes (T2DM) are linked, with obesity causing both precursors and exacerbators of diabetes-related complications. With over 2 billion overweight adults and 650 million obese, lifestyle modifications and medical management are crucial. Emerging therapies like semaglutide offer promising treatments. Addressing obesity and diabetes requires a shift in public health strategy, community engagement, and a holistic understanding of lifestyle, metabolism, and environmental influences.

Interplay between gut microbiota and immunity

The gut microbiota composition significantly influences immune responses in metabolic diseases, with specific taxa being associated with inflammation, insulin resistance, and

metabolic dysfunctions. Studies indicate that alterations in gut microbiota can lead to dysbiosis, exacerbating conditions such as obesity, diabetes, and other metabolic disorders.
The interplay between gut microbiota and immune responses in metabolic diseases has garnered considerable attention over recent years. The dysbiotic state of gut microbiota has been implicated in various metabolic conditions, evidenced by the systematic reviews examined.

Notably, Salles et al. (2020) conducted a systematic review of 27 interventions involving probiotics' effects on insulin resistance. They highlighted that while animal studies generally showed significant improvements in insulin resistance, human trials yielded mixed results, with only five of seven randomized clinical trials showing beneficial effects. This variation underscores the complexity of gut microbiota interactions in metabolic regulation; significant differences were observed in the response based on the individual's baseline microbiome composition and dietary habits.[11]

In a systematic review by Cortijo-Alfonso et al. (2024), 16 randomized controlled trials, with a total of 1,091 individuals, assessed the effects of barley and oat consumption on immune responses and gut microbiota. The analysis found that whole grains positively influenced gut microbiota composition and exhibited anti-inflammatory effects particularly in metabolically at-risk populations, further substantiating the connection between dietary fiber intake, gut microbiota, and immune modulation.[12]

Chibuye et al. (2024) explored the associations between gut microbiome composition and stunting in children under five, synthesizing data from 14 studies across various low- and middle-income countries. They found that children with stunting exhibited a dysbiotic microbiota profile characterized by high levels of pathobionts and reduced butyrate-producing bacteria, which are crucial for immune regulation and health.[13] This suggests that malnutrition's influence on gut microbiota composition may exacerbate developmental immune deficiencies.

The role of short-chain fatty acids (SCFAs) produced by gut microbes in mediating gut-brain interactions is further stressed by Moțățăianu et al. (2023), linking SCFAs to various physiological processes including inflammation and insulin sensitivity. They indicated that dietary components fostering diverse microbial populations could potentially mitigate neurodegenerative and metabolic disorders through SCFA production.[14]

A growing body of evidence suggests that certain microbial taxa, specifically Akkermansia muciniphila and Faecalibacterium prausnitzii, are associated with healthier metabolic outcomes. Studies have shown that these taxa can regulate intestinal barrier function and modulate inflammatory responses, thus playing protective roles against metabolic diseases. For instance, Badal et al. (2020) highlighted that age-associated alterations in microbiota included increased levels of beneficial microbes producing SCFAs, which could potentially offset metabolic deterioration.[15]

Calero-Medina et al. (2023) illustrated how endocrine disruptors could induce microbiota dysbiosis, further impairing metabolic health via immune modulation. Their systematic review underscored the link between environmental exposures and gut health, emphasizing the potential for these chemicals to exacerbate existing metabolic disorders.[16]

Haneishi et al. (2023) noted the critical nature of gut microbiota in the pathogenesis of inflammatory bowel diseases, which often overlap with metabolic disorders, highlighting the need for a nuanced understanding of microbiota contributions to metabolic dysregulations.[17]

The current literature collectively suggests that gut microbiota influence immune responses that can either mitigate or exacerbate metabolic diseases. The dysbiosis observed across various studies implies a multifaceted interaction between diet, microbial communities, and host immune function, warranting further investigation into potential therapeutic strategies targeting the gut microbiome to ameliorate metabolic diseases.

In summary, the relationship between gut microbiota composition and immune responses in metabolic diseases is complex and multifactorial. Emerging evidence suggests that microbial diversity and specific taxa play critical roles in modulating immunity and metabolic functions. Dysbiosis can lead to persistent inflammation and metabolic dysfunctions, indicating potential therapeutic avenues for dietary and probiotic interventions. Future research must focus on elucidating the causative mechanisms and longitudinal effects of microbiome modulation in diverse populations to develop tailored strategies for metabolic disease management.

1. Gut Microbiome Dysbiosis in Obesity

Gut dysbiosis in obesity is characterized by reduced microbial diversity and altered composition, particularly a decrease in beneficial taxa such as Firmicutes and

Bifidobacterium, alongside an increase in potentially harmful taxa like Proteobacteria. Evidence suggests links between gut dysbiosis, inflammation, and metabolic dysfunction, necessitating further investigation into therapeutic strategies that target microbial imbalances.

The investigation of gut dysbiosis in obesity is crucial given its implications for metabolic health. The examined literature delineates clear associations between obesity and specific shifts in gut microbiota composition, predominantly characterized by reduced diversity and alterations in dominant microbial populations. A notable systematic review reported a significant decrease in microbial diversity (α-diversity) among obese individuals compared to their healthy counterparts.[18] This is pivotal since lower diversity is often correlationally linked to obesity-related disorders, including metabolic syndrome and type 2 diabetes mellitus.

The systematic review by Seganfredo et al. provided a comprehensive analysis of 43 studies investigating various weight-loss interventions, such as dietary modifications and bariatric surgery. The analysis revealed that restrictive dietary practices often led to a decline in beneficial phyla, particularly the butyrate-producing Firmicutes, which are crucial for maintaining gut health.[19] In contrast, post-bariatric surgery observations pointed towards increased microbial diversity and a shift towards a healthier gut microbiome profile, underscoring the potential reversibility of dysbiosis through surgical interventions.[18]

Further, specific bacterial taxa were implicated in metabolic health outcomes in an extensive review concerning the gut microbiota and physical exercise in obesity and diabetes.[20,21] This review corroborated findings of increased Bifidobacteria and Akkermansia genera post-exercise, which were associated with improved metabolic profiles, thereby linking physical activity directly to microbial health modifications.

The meta-analysis by Ojo et al. noted the importance of dietary fiber, revealing that increased consumption leads to higher populations of beneficial microbes like Bifidobacterium, highlighting the integral role of diet in modulating dysbiosis.[22] The strong statistical difference ($p < 0.01$) between dietary fiber and placebo groups emphasizes the potential of dietary strategies in correcting dysbiosis.

Emerging evidence has also pointed towards the role of food additives as disruptors of gut microbiota equilibrium, which may exacerbate the conditions leading to dysbiosis.[23] The

systematic review by Singh et al. suggested that specific additives could instigate inflammation and interfere with microbial diversity, implicating a dietary quality aspect in the dysbiotic state associated with obesity.

Moreover, several studies have highlighted metabolic consequences stemming from dysbiosis, with alterations in short-chain fatty acid (SCFA) production as a common biochemical consequence of pathological gut microbiota compositions. SCFAs like butyrate are considered protective against obesity-related metabolic disorders, as they play integral roles in regulating inflammation and glucose metabolism.[24,25]

In critically assessing the quality of the evidence, the systematic reviews displayed high levels of evidence (Level I and II) due to their extensive data collection and methodological rigor, primarily utilizing PRISMA guidelines for systematic searches. However, some individual studies still lack the depth of longitudinal data, raising concerns regarding the causality between dysbiosis and weight gain.

The integration of findings from the examined literature elucidates a cohesive understanding of gut dysbiosis in obesity, marked by diminished microbial diversity and shifts towards pathogenic taxa. The substantial evidence correlating lower diversity with obesity-related health issues signals a pressing need for interventions targeting gut microbiota rebalancing. Strategies such as dietary modifications emphasizing fiber intake, physical activity engagement, and possibly the implementation of prebiotics and probiotics could provide avenues for therapeutic interventions.

Moreover, the acknowledgement of the negative influences of processed food additives on gut microbiota diversity necessitates public health initiatives focused on improving dietary choices among populations at risk for obesity. The dynamic interplay between diet, physical activity, and microbial health warrants continued research to uncover precise mechanisms underlying these relationships.

Understanding how therapeutic strategies could not only mitigate the dysbiotic state but also offer protection against weight gain and metabolic disturbances could pave the way for novel interventions in obesity management. Future research needs to focus on robust clinical trials that explore the efficacy of microbiota-targeted therapies in treating obesity and its comorbid conditions.

2. Immune Responses Mediated by Gut Microbiota

The relationship between gut microbiota and immune responses has garnered increased attention, particularly in light of the findings regarding the gut-microbiota-brain axis and its implications for both physical and mental health.[26,27] For instance, the recent systematic review by Fan et al. (2023) establishes a robust link between dietary nutrients, gut microbiota composition, and host immune function. Their investigation presents compelling evidence that alterations in dietary intake can significantly modulate gut microbiota diversity and, in turn, influence disease patterns related to immune-mediated conditions.[26] They highlight that a more diverse microbiota is generally associated with improved immune responses, suggesting that diet should be considered as a primary intervention point for enhancing gut microbiota health.

Further, the systematic review by Qiu et al. (2022) provides insight into the mechanisms through which gut microbiota dysfunction contributes to chronic conditions such as inflammatory bowel disease (IBD). IBD is characterized by dysregulation of the immune response, leading to inflammation and damage in the gastrointestinal tract. The authors synthesize evidence indicating that dysbiosis—characterized by an imbalance of microbial populations—can exacerbate disease via increased intestinal permeability and enhanced immune activation.[28] The review includes data from over 26 studies, underscoring the importance of this relationship in IBD pathogenesis.

The role of exercise-induced stress on gut microbiota and the associated psychobiotic effects is explored in Clark and Mach's 2016 systematic review, which outlines the significant interaction between physical stress, dietary influences, and gut microbiota alterations, demonstrating a clear feedback loop affecting immune responses.[27] The psychological impact of dysbiosis, including its potential to influence mood and behavior through inflammatory pathways, is reinforced in the findings of Barrio et al. (2022), who discuss the gut-brain axis and its implication in neuropsychiatric disorders, thereby indicating a bi-directional relationship between gut health and systemic immunity.[29]

Moreover, the implications of investigating prebiotics, probiotics, and dietary fiber are emphasized as potential therapeutic strategies for restoring microbiota balance and enhancing immune response. For example, studies demonstrate that probiotics can alter gut microbiota composition favorably and lead to improved clinical outcomes in conditions such as anxiety.[30]

Taken together, the current body of evidence from systematic reviews demonstrates that gut microbiota not only reflects individual health status but plays an intrinsic role in modulating immune responses across a spectrum of diseases, including metabolic syndrome, neurodegeneration, and autoimmune disorders.

The synthesis of remaining literature underscores the pivotal role gut microbiota plays in regulating immune responses and maintaining homeostasis. Dysbiosis is consistently associated with a myriad of immune-related health issues, highlighting the need for interventions that can restore microbial balance. Both dietary adjustments and targeted therapeutic interventions, such as fecal microbiota transplantation, are proposed as viable strategies for mitigating dysbiosis and enhancing host immunity. Moving forward, the integration of microbiome-focused approaches into conventional treatment modalities could revolutionize the management of immune-mediated diseases.

3. Linking Gut Microbiome to Insulin Resistance and Diabetes Progression

The gut microbiome, which consists of trillions of microorganisms residing in our intestines, plays a crucial role in human health, particularly in metabolic processes. Recent research has increasingly focused on the link between the gut microbiome and the development of insulin resistance and type 2 diabetes mellitus (T2DM). Insulin resistance is a state in which the body's cells do not respond well to insulin, resulting in elevated blood glucose levels, which is a hallmark of T2DM. The interplay between gut microbiota and diabetes offers potential insights into novel therapeutic strategies for managing and preventing T2DM.

Emerging evidence suggests that dysbiosis, or an imbalance in the gut microbial community, is closely associated with insulin resistance and T2DM. Studies have documented that the composition of gut microbiota differs significantly between individuals with T2DM and those with normal glucose tolerance. For instance, individuals with T2DM often show reduced diversity in their gut microbiota, alongside higher levels of certain bacterial taxa such as Firmicutes and a decrease in beneficial species like Bacteroidetes and Faecalibacterium prausnitzii.[31,32] This dysbiosis may contribute to chronic inflammation and impaired metabolism, reinforcing the cycle of insulin resistance.[33,34]

Notably, specific gut bacteria have been implicated in modulating the metabolism of short-chain fatty acids (SCFAs), which are pivotal in maintaining insulin sensitivity. Increased SCFA production, often linked to higher dietary fiber intake, can enhance the secretion of

hormones like glucagon-like peptide-1 (GLP-1) that improve glucose metabolism.[35,36] Furthermore, certain strains such as Bifidobacterium and Akkermansia muciniphila have demonstrated protective effects against insulin resistance, suggesting that probiotics could be a viable strategy for T2DM management.[37,38]

The impact of diet on gut microbiota composition is also significant. Diets high in fiber and low in sugars and fats have promoted beneficial changes in the gut flora, leading to improved metabolic health outcomes.[39,40] For example, systematic reviews have confirmed that dietary interventions increasing fiber intake can foster a gut microbiome that supports better glucose control and lower insulin resistance.[41] Additionally, emerging studies suggest the potential role of dietary patterns, such as the Mediterranean diet, in positively influencing gut health and metabolic parameters in individuals with T2DM.[42]

Moreover, the relationship between gut microbiota and T2DM is bidirectional. While dysbiosis can promote the onset of T2DM, diabetes itself can further alter the gut microbiome. Insulin resistance may lead to metabolic changes that affect the composition and function of gut bacteria, creating a self-perpetuating cycle of worsening metabolic health.[43] This complex relationship underlines the need for interventions targeting both microbial health and metabolic function.

Overall, gut microbiota offers a promising area for research aimed at understanding the pathogenesis of T2DM and developing targeted treatments. Future studies and clinical trials focused on manipulating the gut microbiome through dietary changes, prebiotics, probiotics, and possibly fecal microbiota transplantation are needed to validate these findings and explore their therapeutic potential.[44,45]

While progress has been made in characterizing the links between gut microbiota and insulin resistance, significant gaps remain in our understanding of the specific mechanisms involved. Further research is required to elucidate the networks between different microbial taxa, their metabolic pathways, and their impact on human physiology under varying dietary and health conditions. As knowledge in this area expands, it may facilitate the development of innovative preventive and treatment strategies for T2DM.

Future Directions

The relationship between gut microbiota composition and metabolic diseases is complex, with the exact mechanisms being unclear. Future research should focus on understanding the specific microbial metabolites and immune pathways contributing to insulin resistance and chronic inflammation. Long-term cohort studies are essential to establish temporal relationships and causative links, which could inform the development of predictive biomarkers for disease onset and progression. Personalized therapeutic approaches targeting the microbiome may enhance treatment efficacy, such as dietary modifications, probiotics, or microbiota transplants tailored to a person's unique microbiome. Integrating genomics, transcriptomics, metabolomics, and metagenomics data can provide a holistic understanding of host-microbiome interactions, potentially identifying novel therapeutic targets and biomarkers for metabolic diseases. Additionally, exploring gut-brain axis interactions could reveal new intervention points for obesity and diabetes. Overall, understanding the complex relationship between gut microbiota and metabolic diseases is crucial for effective management strategies.

Limitations

1. **Complexity of Microbiome Composition**: The vast diversity and dynamic nature of the gut microbiome pose challenges in identifying specific microbial species or communities responsible for metabolic effects. Standardizing methodologies for microbiome analysis and interpretation is crucial to advance the field.
2. **Inter-Individual Variability**: Differences in genetics, diet, environment, and lifestyle among individuals lead to significant variability in gut microbiota composition and function. This heterogeneity complicates the development of universal therapeutic strategies and underscores the need for personalized approaches.
3. **Translational Challenges**: Findings from animal models may not always be directly applicable to humans due to species-specific differences in microbiota and immune system interactions. Bridging this gap requires well-designed human studies to validate preclinical results.
4. **Potential Confounding Factors**: Factors such as diet, medication use (e.g., antibiotics), and comorbid conditions can influence both gut microbiota composition and metabolic health, making it challenging to isolate the effects of the microbiome itself. Careful study design and control of confounding variables are essential in research.

Addressing these future directions and limitations will enhance our understanding of the gut microbiome's role in obesity and diabetes, paving the way for innovative and effective therapeutic strategies.

CONCLUSION

The intricate interplay between the gut microbiome, immune responses, and metabolic health highlights the pivotal role of gut-immune-metabolic crosstalk in the progression of obesity to type 2 diabetes. Alterations in the gut microbiome associated with obesity lead to immune dysregulation, low-grade systemic inflammation, and metabolic dysfunction, all of which contribute to insulin resistance and β-cell impairment. Microbial metabolites, such as short-chain fatty acids and lipopolysaccharides, act as key mediators in these processes, either exacerbating or mitigating inflammation and metabolic disturbances.

Understanding these mechanisms not only deepens our knowledge of diabetes pathogenesis but also opens avenues for innovative therapeutic interventions. Strategies such as modulating the gut microbiome with probiotics, prebiotics, dietary changes, and fecal microbiota transplantation hold promise in restoring microbial balance and improving metabolic outcomes. However, significant challenges remain, including the complexity of individual microbiomes, the need for personalized interventions, and the translation of findings from research to clinical practice.

Future studies should aim to unravel the precise molecular pathways linking the gut microbiome to immune and metabolic dysfunction, develop predictive biomarkers for diabetes progression, and design targeted therapies tailored to individual microbiome profiles. By addressing these gaps, we can harness the therapeutic potential of the gut microbiome to combat the global burden of obesity and diabetes effectively.

REFERENCES

1. Caballero B. Humans against Obesity: Who Will Win? Advances in Nutrition, Jan. 1, 2019; 10: S4–9.
2. Safaei M, Sundararajan EA, Driss M, Boulila W, Shapi'i A. A systematic literature review on obesity: Understanding the causes & consequences of obesity and reviewing various machine learning approaches used to predict obesity. Comput Biol Med., Sep. 1, 2021; 136.

3. Klein S, Gastaldelli A, Yki-Järvinen H, Scherer PE. Why does obesity cause diabetes? Cell Metab, Jan. 4, 2022; 34(1): 11–20.
4. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol, Oct. 1, 2019; 71(4): 793–801.
5. Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, Dec. 1, 2022; 20(12): 2809-2817.e28.
6. Ahirwar R, Mondal PR. Prevalence of obesity in India: A systematic review. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, Jan. 1, 2019; 13(1): 318–21.
7. Rubio-Almanza M, Cámara-Gómez R, Merino-Torres JF. Obesity and type 2 diabetes: Also linked in therapeutic options. Endocrinol Diabetes Nutr., Mar. 1, 2019; 66(3): 140–9.
8. Chandrasekaran P, Weiskirchen R. The Role of Obesity in Type 2 Diabetes Mellitus-An Overview. Int J Mol Sci [Internet]. 2024 Feb 4 [cited 2024 Dec 19]; 25(3). Available from: http://www.ncbi.nlm.nih.gov/pubmed/38339160
9. Ruze R, Liu T, Zou X, Song J, Chen Y, Xu R, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol (Lausanne) [Internet]. 2023 [cited 2024 Dec 19]; 14: 1161521. Available from: http://www.ncbi.nlm.nih.gov/pubmed/37152942
10. Irfan H. Obesity, Cardiovascular Disease, and the Promising Role of Semaglutide: Insights from the SELECT Trial. Curr Probl Cardiol, Jan. 1, 2024; 49(1).
11. Salles BIM, Cioffi D, Ferreira SRG. Probiotics supplementation and insulin resistance: a systematic review. Diabetol Metab Syndr [Internet]. 2020 Nov 11 [cited 2024 Dec 22]; 12(1): 98. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33292434
12. Cortijo-Alfonso ME, Romero MP, Macià A, Yuste S, Moralejo M, Rubió-Piqué L, et al. Effect of Barley and Oat Consumption on Immune System, Inflammation and Gut Microbiota: A Systematic Review of Randomized Controlled Trials. Curr Nutr Rep., Sep. 1, 2024; 13(3): 582–97.
13. Chibuye M, Mende DR, Spijker R, Simuyandi M, Luchen CC, Bosomprah S, et al. Systematic review of associations between gut microbiome composition and stunting in under-five children. NPJ Biofilms Microbiomes, Dec. 1, 2024; 10(1).

14. Moianu A, Șerban G, Andone S. The Role of Short-Chain Fatty Acids in Microbiota–Gut–Brain Cross-Talk with a Focus on Amyotrophic Lateral Sclerosis: A Systematic Review. Int J Mol Sci., Oct. 1, 2023; 24(20).
15. Badal VD, Vaccariello ED, Murray ER, Yu KE, Knight R, Jeste D V., et al. The gut microbiome, aging, and longevity: A systematic review. Nutrients, Dec. 1, 2020; 12(12): 1–25.
16. Calero-Medina L, Jimenez-Casquet MJ, Heras-Gonzalez L, Conde-Pipo J, Lopez-Moro A, Olea-Serrano F, et al. Dietary exposure to endocrine disruptors in gut microbiota: A systematic review. Science of the Total Environment, Aug. 15, 2023; 886.
17. Tong Y, Gao H, Qi Q, Liu X, Li J, Gao J, et al. High fat diet, gut microbiome and gastrointestinal cancer. Theranostics, 2021; 11(12): 5889–910.
18. Gentile JKA, Oliveira KD, Pereira JG, Tanaka DY, Guidini GN, Cadona MZ, et al. The intestinal microbiome in patients undergoing bariatric surgery: A systematic review. Arquivos Brasileiros de Cirurgia Digestiva, 2022; 35.
19. Abenavoli L, Scarpellini E, Colica C, Boccuto L, Salehi B, Sharifi-Rad J, et al. Gut microbiota and obesity: A role for probiotics. Nutrients, Nov. 1, 2019; 11(11).
20. Barko PC, McMichael MA, Swanson KS, Williams DA. The Gastrointestinal Microbiome: A Review. J Vet Intern Med., Jan. 1, 2018; 32(1): 9–25.
21. Silva JSC, Seguro CS, Naves MM V. Gut microbiota and physical exercise in obesity and diabetes – A systematic review. Nutrition, Metabolism and Cardiovascular Diseases, Apr. 1, 2022; 32(4): 863–77.
22. Singh S, Olayinka OT, Fr J, Nisar MR, Kotha R, Saad-Omer SI, et al. Food Additives' Impact on Gut Microbiota and Metabolic Syndrome: A Systematic Review. Cureus [Internet]. 2024 Aug 14 [cited 2024 Dec 22]; 16(8): e66822. Available from: http://www.ncbi.nlm.nih.gov/pubmed/39280570
23. Dziewiecka H, Buttar HS, Kasperska A, Ostapiuk–Karolczuk J, Domagalska M, Cichoń J, et al. Physical activity induced alterations of gut microbiota in humans: a systematic review. BMC Sports Sci Med Rehabil, Dec. 1, 2022; 14(1).
24. Nikkhah A, Ejtahed HS, Ettehad Marvasti F, Taghavi MS, Pakmehr A, Hajipour F, et al. The critical role of gut microbiota dysbiosis in skeletal muscle wasting: a systematic review. J Appl Microbiol, Jan. 1, 2023; 134(1).
25. Ahlawat S, Asha, Sharma KK. Gut–organ axis: a microbial outreach and networking. Lett Appl Microbiol, Jun. 1, 2021; 72(6): 636–68.

26. Fan L, Xia Y, Wang Y, Han D, Liu Y, Li J, et al. Gut microbiota bridges dietary nutrients and host immunity. Sci China Life Sci., Nov. 2023; 66(11): 2466–514.
27. Clark A, Mach N. Exercise-induced stress behavior, gut-microbiota-brain axis and diet: a systematic review for athletes. J Int Soc Sports Nutr., 2016; 13: 43.
28. Qiu P, Ishimoto T, Fu L, Zhang J, Zhang Z, Liu Y. The Gut Microbiota in Inflammatory Bowel Disease. Front Cell Infect Microbiol, Feb. 22, 2022; 12.
29. Barrio C, Arias-Sánchez S, Martín-Monzón I. The gut microbiota-brain axis, psychobiotics and its influence on brain and behaviour: A systematic review. Psychoneuroendocrinology, Mar. 2022; 137: 105640.
30. Joubert M, André M, Barnich N, Billard E. Microbiome and Behçet's disease: a systematic review. Clin Exp Rheumatol, Oct. 1, 2023; 41(10): 2093–104.
31. Letchumanan G, Abdullah N, Marlini M, Baharom N, Lawley B, Omar MR, et al. Gut Microbiota Composition in Prediabetes and Newly Diagnosed Type 2 Diabetes: A Systematic Review of Observational Studies. Front Cell Infect Microbiol, Aug. 15, 2022; 12.
32. Ojo O, Feng QQ, Ojo OO, Wang XH. The role of dietary fibre in modulating gut microbiota dysbiosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomised controlled trials. Nutrients, Nov. 1, 2020; 12(11): 1–21.
33. Slouha E, Rezazadah A, Farahbod K, Gerts A, Clunes LA, Kollias TF. Type-2 Diabetes Mellitus and the Gut Microbiota: Systematic Review. Cureus [Internet]. 2023 Nov 30 [cited 2024 Dec 22]; 15(11): e49740. Available from: http://www.ncbi.nlm.nih.gov/pubmed/38161953
34. Yao X, Geng S, Zhu L, Jiang H, Wen J. Environmental pollutants exposure and gestational diabetes mellitus: Evidence from epidemiological and experimental studies. Chemosphere, Aug. 1, 2023; 332.
35. Mindrescu NM, Guja C, Jinga V, Ispas S, Curici A, Nelson Twakor A, et al. Interactions between Gut Microbiota and Oral Antihyperglycemic Drugs: A Systematic Review. Int J Mol Sci., Mar. 1, 2024; 25(6).
36. Ma S, Wang Y, Ji X, Dong S, Wang S, Zhang S, et al. Relationship between gut microbiota and the pathogenesis of gestational diabetes mellitus: a systematic review. Front Cell Infect Microbiol, 2024; 14.
37. Zhang S, Deng F, Chen J, Chen F, Wu Z, Li L, et al. Fecal microbiota transplantation treatment of autoimmune-mediated type 1 diabetes: A systematic review. Front Cell Infect Microbiol, Dec. 1, 2022; 12.

38. Górowska-Kowolik K, Chobot A. The role of gut micorbiome in obesity and diabetes. World Journal of Pediatrics, Aug. 1, 2019; 15(4): 332–40.
39. Sadagopan A, Mahmoud A, Begg M, Tarhuni M, Fotso M, Gonzalez NA, et al. Understanding the Role of the Gut Microbiome in Diabetes and Therapeutics Targeting Leaky Gut: A Systematic Review. Cureus, Jul. 8, 2023.
40. Farahbod K, Slouha E, Gerts A, Rezazadah A, Clunes LA, Kollias TF. The Effects of Diet Intervention on the Gut Microbiota in Type 2 Diabetes Mellitus: A Systematic Review. Cureus [Internet]. 2024 Mar 23 [cited 2024 Dec 22]; 16(3): e56737. Available from: http://www.ncbi.nlm.nih.gov/pubmed/38646363
41. Iatcu CO, Steen A, Covasa M. Gut microbiota and complications of type-2 diabetes. Nutrients, Jan. 1, 2022; 14(1).
42. Gurung M, Li Z, You H, Rodrigues R, Jump DB, Morgun A, et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine, Jan. 1, 2020; 51.
43. Dabke K, Hendrick G, Devkota S. The gut microbiome and metabolic syndrome. Journal of Clinical Investigation, Oct. 1, 2019; 129(10): 4050–7.
44. Wu J, Yang K, Fan H, Wei M, Xiong Q. Targeting the gut microbiota and its metabolites for type 2 diabetes mellitus. Front Endocrinol (Lausanne) [Internet]. 2023 [cited 2024 Dec 22]; 14: 1114424. Available from: http://www.ncbi.nlm.nih.gov/pubmed/37229456
45. Zhou Z, Sun B, Yu D, Zhu C. Gut Microbiota: An Important Player in Type 2 Diabetes Mellitus. Front Cell Infect Microbiol, Feb. 15, 2022; 12.